Viewing Study NCT00358293


Ignite Creation Date: 2025-12-25 @ 1:10 AM
Ignite Modification Date: 2025-12-25 @ 11:21 PM
Study NCT ID: NCT00358293
Status: COMPLETED
Last Update Posted: 2009-01-21
First Post: 2006-07-27
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Sponsor: Teva GTC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module